On September 20, 2021 Seagen Inc. (Nasdaq: SGEN) reported that it will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK (tisotumab vedotin-tftv) (Press release, Seagen, SEP 20, 2021, View Source [SID1234587994]). Access to the event can be obtained as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

September 21, 2021

6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time

Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160278
Webcast with slides will be available at www.seagen.com in the Investors section. A webcast replay will be archived on the Company’s website.